WebJan 4, 2024 · A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D … WebFeb 6, 2024 · Biogen Inc. and C4 Therapeutics Inc. have synthesized proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to an IL-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.
Biogen and C4 divulge new IRAK-4 degradation inducers
WebApr 10, 2024 · NEW YORK – C4 Therapeutics is steadily moving its BRD9- and BRAF-V600X-targeted protein degraders into the clinic hoping to demonstrate their benefits over protein inhibitors currently on the market. WebC4 Therapeutics has hired Adam Crystal, M.D., Ph.D., a senior director at the Novartis Institutes for BioMedical Research, to be its new chief medical officer and help carry its … greenroofed hobbit prefab home price
Biogen partneres with C4 Therapeutics to address neurological …
WebMar 11, 2024 · Revenue: Total revenue for the year ended December 31, 2024 was $33.2 million, compared to $21.4 million for the year ended December 31, 2024. Total revenue reflects revenue recognized under ... WebJan 7, 2024 · Biogen has signed a strategic collaboration with C4 Therapeutics for the discovery and development of new therapies to treat neurological diseases, including Alzheimer's disease. The partners will explore the use of C4 Therapeutics new protein degradation platform to identify new treatments. WebJan 10, 2024 · Biogen (Nasdaq: BIIB) will pay Cambridge’s Camp4 Therapeutics $15 million upfront to help develop new therapies for neurological and neurodegenerative diseases. The deal could also earn Camp4... greenroofed hobbit prefab home kit cost